Literature DB >> 10051258

Analysis of risk factors for the development of bronchiolitis obliterans syndrome.

A N Husain1, M T Siddiqui, E W Holmes, A J Chandrasekhar, M McCabe, R Radvany, E R Garrity.   

Abstract

Chronic rejection after lung transplantation, manifesting as bronchiolitis obliterans syndrome (BOS), has become the dominant challenge to long-term patient and graft survival. In order to elucidate risk factors for development of BOS we utilized the 1995 revision of the working formulation for the classification of lung allograft rejection (), and devised a quantitative method to retrospectively study lung transplant biopsies from all patients who survived at least 90 d. All transbronchial biopsies were regraded 0 to 4 for acute perivascular rejection and lymphocytic bronchitis/bronchiolitis (LBB), and the grades were totaled over a period of time to give two scores, respectively, for each patient. Also examined were timing of acute rejection and LBB episodes and decreased immunosuppression defined as two or more cyclosporine A levels < 200 ng/ml. Sixty-six patients with BOS and 68 with no BOS (NBOS) satisfied our criteria for inclusion in the study. Demographics including age, sex, and primary diagnoses were similar. The mean perivascular score for BOS was 6.2 over a mean follow-up of 822 d (range, 113 to 2,146) compared with 3.2 for NBOS over 550 d (range, 97 to 1,734) mean follow-up. Airway scores were 5.3 and 1.7, respectively, for the same follow-up periods. There was no correlation between length of follow-up and rejection or LBB scores, although mean length of follow-up for the two groups was significantly different. Late acute rejection and LBB were significantly associated with BOS as was decreased immunosuppression. In addition to perivascular rejection, LBB, late acute rejection, and decreased immunosuppression are significant risk factors for the development of BOS. Analysis of the current data leads us to believe that LBB, in the absence of infection, is in fact a manifestation of acute rejection, with similar implications for graft function as acute perivascular rejection.

Entities:  

Mesh:

Year:  1999        PMID: 10051258     DOI: 10.1164/ajrccm.159.3.9607099

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  50 in total

1.  The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome.

Authors:  A DerHovanessian; S S Weigt; V Palchevskiy; M Y Shino; D M Sayah; A L Gregson; P W Noble; S M Palmer; M C Fishbein; B M Kubak; A Ardehali; D J Ross; R Saggar; J P Lynch; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2015-10-13       Impact factor: 8.086

Review 2.  Lung transplantation: opportunities for research and clinical advancement.

Authors:  David S Wilkes; Thomas M Egan; Herbert Y Reynolds
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

Review 3.  Novel insights into lung transplant rejection by microarray analysis.

Authors:  Jeffrey D Lande; Jagadish Patil; Na Li; Todd R Berryman; Richard A King; Marshall I Hertz
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 4.  Human and murine obliterative bronchiolitis in transplant.

Authors:  John F McDyer
Journal:  Proc Am Thorac Soc       Date:  2007-01

Review 5.  Mechanisms of chronic rejection in cardiothoracic transplantation.

Authors:  Matthew J Weiss; Joren C Madsen; Bruce R Rosengard; James S Allan
Journal:  Front Biosci       Date:  2008-01-01

6.  Adherence to the medical regimen during the first two years after lung transplantation.

Authors:  Mary Amanda Dew; Andrea F Dimartini; Annette De Vito Dabbs; Rachelle Zomak; Sabina De Geest; Fabienne Dobbels; Larissa Myaskovsky; Galen E Switzer; Mark Unruh; Jennifer L Steel; Robert L Kormos; Kenneth R McCurry
Journal:  Transplantation       Date:  2008-01-27       Impact factor: 4.939

7.  Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.

Authors:  S S Weigt; R M Elashoff; C Huang; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; M P Keane; R Saggar; J P Lynch; D A Zisman; D J Ross; J A Belperio
Journal:  Am J Transplant       Date:  2009-05-13       Impact factor: 8.086

8.  Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection.

Authors:  Aric L Gregson; Aki Hoji; Rajan Saggar; David J Ross; Bernard M Kubak; Beth D Jamieson; S Samuel Weigt; Joseph P Lynch; Abbas Ardehali; John A Belperio; Otto O Yang
Journal:  Transplantation       Date:  2008-04-15       Impact factor: 4.939

9.  Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens.

Authors:  Xiang Xu; Jeffrey A Golden; Gregory Dolganov; Kirk D Jones; Samantha Donnelly; Timothy Weaver; George H Caughey
Journal:  J Heart Lung Transplant       Date:  2005-08       Impact factor: 10.247

10.  Medication Nonadherence After Lung Transplantation in Adult Recipients.

Authors:  Anthony W Castleberry; Muath Bishawi; Mathias Worni; Loretta Erhunmwunsee; Paul J Speicher; Asishana A Osho; Laurie D Snyder; Matthew G Hartwig
Journal:  Ann Thorac Surg       Date:  2016-09-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.